Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-23

Study Completion Date

2019-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this project is to Compare new msCS and standard DSC-PWI methods in GBM patients undergoing post-operative MRI for monitoring of tumor progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Measuring Non-Enhancing Glioblastoma Progression

NCT00777686

Brain Tumor Glioblastoma

COMPLETED

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

NCT00005790

Brain and Central Nervous System Tumors

WITHDRAWN NA

MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma

NCT00756106

Brain and Central Nervous System Tumors

TERMINATED NA

Spectroscopic Magnetic Resonance Imaging of Glioma

NCT03677999

Brain Tumor-Glioma

WITHDRAWN

Multimodality MRI and Liquid Biopsy in GBM

NCT04776980

Glioblastoma Multiforme Brain Tumor, Adult: Glioblastoma Brain Tumor, Recurrent +1 more

WITHDRAWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will compare the novel to the standard DSC-PWI methods in twenty five GBM patients to determine whether novel method improves image quality in tumor regions. We will also compare accuracy of pseudoprogression (PsP) vs. early progressive disease (ePD) determinations by the two techniques. If successful, the project will culminate in a novel imaging method sequence optimized to monitor progression and guide treatment decisions in post-operative GBM patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Glioblastoma Multiforme

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GBM patients undergoing MRI

GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.

MRI

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histology: Glioblastoma (grade 4 astrocytoma)
* Standard-of-care, post-gd T1w image changes suggestive or consistent with of progression.
* Standard-of-care MRI included conventional DSC-PWI without unexpected technical difficulties.
* Methylation status of tumor available in medical record.
* Able to provide written informed consent.

Exclusion Criteria

* Contraindications either to 3T MRI (e.g. certain metallic and electronic implants, claustrophobia) or IV gadolinium contrast (allergy, pregnancy, breast-feeding, renal insufficiency). Screening for these contraindications will be based on history only (as it is for all routine outpatient clinical MRI at UWHC).
* Significant physical or mental disease which would preclude successful compliance and participation in the study or, in the opinion of the principal investigator, or co-investigator, constitute a hazard, such that enrollment in the study would not be in the patient's best interest.
* Special subjects such as minors, mentally disabled persons, or prisoners.

Minimum Eligible Age

18 Years

Maximum Eligible Age

82 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No